Login to Your Account

AVEO Series D Pulls Down $53M For Cancer Therapies

By Randall Osborne

Friday, May 4, 2007
Cancer-focused AVEO Pharmaceuticals Inc.'s rare balance between antibody and small-molecule discovery bagged $53 million in a Series D financing that leaves the firm with enough cash to last "a little bit short of two years," said Tuan Ha-Ngoc, president and CEO. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription